Winning combination: the additive/synergistic benefits of IVIg in corticosteroid refractory optic neuritis.
Achiron
A
A
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000187:drug effects* / Q000276:immunology; D004357:Drug Synergism; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage; D008775:Methylprednisolone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000150:complications* / Q000276:immunology; D009902:Optic Neuritis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D008775:Methylprednisolone